Philips, the Dutch health technology company, delivered better-than-expected third-quarter earnings while setting aside €288 million for a proposed settlement with the US Department of Justice (DOJ) related to its Respironics sleep-device recall. The company said the payment is expected to be made in the first quarter of 2027.
The news comes as Philips continues to navigate the fallout from the massive recall of its sleep apnea machines, which began in 2021. The proposed DOJ deal is a significant step toward resolving one of the most pressing legal overhangs for the company.
Earnings beat driven by margins and productivity
Philips reported adjusted earnings before interest, taxes, and amortization (adjusted EBITA) of €569 million for the third quarter, a 7.2% increase from the same period last year. That figure came in well above the €522 million consensus estimate the company published, surprising analysts who had braced for a weaker performance.
The earnings beat was fueled by higher sales, improved gross margins, and ongoing productivity efforts. Philips, which makes everything from electric toothbrushes to hospital imaging systems, has been focused on cost discipline and operational efficiency as it works to restore investor confidence.
The company's core profit measure, adjusted EBITA, strips out certain one-time items and amortization charges, giving investors a clearer view of underlying business performance. For everyday investors, this is a key metric to watch because it reflects how well the company is managing its day-to-day operations.
The Respironics recall and the DOJ settlement
The €288 million provision is tied to a proposed settlement with the US Department of Justice over the Respironics sleep-device recall. Respironics, which Philips acquired in 2008, makes continuous positive airway pressure (CPAP) machines and other devices used to treat sleep apnea. In 2021, Philips recalled millions of these devices over concerns that the sound-dampening foam inside them could degrade and be inhaled by users, posing potential health risks.
The recall has been a major drag on Philips, leading to billions in charges, lawsuits, and a sharp decline in its share price. The company has already set aside funds for patient compensation and device replacement, but the DOJ investigation has been a lingering uncertainty. The proposed settlement, if finalized, would remove a significant legal overhang, though it is not yet a done deal.
Philips said the payment is expected to be made in the first quarter of 2027, which gives the company time to manage its cash flow. For investors, this means the financial impact is known and scheduled, reducing the risk of a sudden, larger hit down the road.
What it means for investors
For everyday investors, the key takeaway is that Philips is making progress on two fronts: improving its core business and resolving a major legal issue. The earnings beat suggests the company's turnaround efforts are gaining traction, while the DOJ settlement provision, though costly, brings clarity to a long-running uncertainty.
However, the settlement is not yet final, and the DOJ could still seek different terms. Investors should also note that the €288 million charge is separate from other costs related to the recall, such as device replacements and patient compensation, which have already been substantial.
Philips' performance also comes against a broader backdrop of mixed earnings reports from major companies. For instance, Apple beat estimates on strong iPhone demand, while Mondelez beat Q3 but gave a soft Q4 outlook. In the healthcare sector, healthcare stocks have been split, with some names surging and others falling.
Looking ahead, investors will be watching for final approval of the DOJ settlement, as well as any further updates on the recall's financial impact. They'll also be monitoring whether Philips can sustain its margin improvements and sales growth in the coming quarters.
As always, this is not a recommendation to buy or sell Philips stock. But for those who own it or are considering it, the combination of a solid earnings beat and a clearer legal path is a positive sign, though risks remain.
